AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
| Revenue (TTM) | $61.37B |
| Gross Profit (TTM) | $50.13B |
| EBITDA | $19.90B |
| Operating Margin | 23.50% |
| Return on Equity | 22.00% |
| Return on Assets | 8.02% |
| Revenue/Share (TTM) | $39.59 |
| Book Value | $32.43 |
| Price-to-Book | 5.23 |
| Price-to-Sales (TTM) | 4.32 |
| EV/Revenue | 4.793 |
| EV/EBITDA | 14.45 |
| Quarterly Earnings Growth (YoY) | 2.50% |
| Quarterly Revenue Growth (YoY) | 6.40% |
| Shares Outstanding | $1.55B |
| Float | $1.54B |
| % Insiders | 0.05% |
| % Institutions | 68.33% |
Volatility is currently contracting
NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC (“AstraZeneca” or the “Company”) (NYSE: AZN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) drug pipeline is splitting opinion among City brokers, with Citibank upgrading its price target to 17,800p whilst analysts at Deutsche Bank repeated a 'sell' rating and a 11,500p valuation. Shares in the FTSE 100 drugmaker were down 1.1% at 12,744p on Tuesday afternoon.
AstraZeneca tops Q2 earnings and revenue estimates as strong demand for oncology and rare disease drugs helps offset growing generic competition across key products.
AstraZeneca PLC delivered solid Q2 2026 core EPS growth of 18% YoY, while revenue growth came in line with expectations for the full year 2026. There could be challenges in store, though, with Farxiga, the company's biggest treatment, seeing patent expiry in the U.S. and coming under China's procurement program. Balancing out the challenges to some extent are the results of the company's weight loss drug candidate, elecoglipron, and the stock's improved market valuations.
While the top- and bottom-line numbers for Astrazeneca (AZN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Astrazeneca NYSE: AZN reported first-half 2026 revenue growth of 6% at constant exchange rates, or 11% excluding the effects of generic competition on Farxiga and Brilinta, while core earnings per share increased 11%. The company reiterated its full-year outlook and said it remains confident in its goal of reaching $80 billion in revenue by 2030.
AstraZeneca has been adjusting its pricing strategy for new drug launches in response to U.S. President Donald Trump's "most-favoured-nation" policy seeking lower drug prices for Americans, a senior company executive said on Monday.
AstraZeneca said on Monday its rare disease drug Ultomiris failed a late-stage trial in patients with a blood vessel complication following a stem cell transplant, the latest in a series of setbacks this year that have fuelled concerns about the drugmaker's pipeline.
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) reported better second-quarter earnings than expected as growth in oncology and rare diseases helped offset weaker sales elsewhere. Total revenue increased 9% to $30.7 billion in the first half of 2026, or 6% at constant exchange rates.
The U.K. drugmaker's revenue rose 5% when adjusted for currency changes, driven by growth in oncology sales.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on AZN and any ticker you trade — then tracks every position and per-strategy win rate.
